Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, pharmacokinetics, and early activity of GDC-7035, both alone and combined with other anti-cancer therapies, in adults with advanced or metastatic solid tumors that have the KRAS G12D mutation. This first-in-human Phase III study is open-label and conducted at multiple centers, focusing on patients with this specific genetic tumor marker. Participants receive GDC-7035 in two study arms one with GDC-7035 alone and the other with GDC-7035 combined with other anti-cancer treatments. The study involves dose escalation and expansion phases with protocol-defined dosing to determine safe and effective dose levels. During the trial, participants are closely monitored for side effects, dose-limiting toxicities, and blood levels of the drug at specified times. Researchers measure response rates, duration of response, and progression-free survival over a period of up to four years. The study involves regular evaluations to assess safety and drug activity throughout the treatment period.